Literature DB >> 34705188

Neuroprotective Effect of Apigenin on Depressive-Like Behavior: Mechanistic Approach.

Ali Sharafi1,2, Mir-Jamal Hosseini3,4, Soroush Bijani5,6, Rana Dizaji5.   

Abstract

Apigenin, as a natural flavonoid present in several plants is characterized with potential anticancer, antioxidant, and anti-inflammatory properties. Recent studies proposed that apigenin affects depression disorder through unknown mechanistic pathways. The effects of apigenin's anti-depressive properties on streptozocin-mediated depression have been investigated through the evaluation of behavioral tests, oxidative stress, cellular energy homeostasis and inflammatory responses. The results demonstrated anti-depressive properties of apigenin in behavioral test including forced swimming and splash tests and oxidative stress biomarkers such as reduced glutathione, lipid peroxidation, total antioxidant power and coenzyme Q10 levels. Apigenin, also, demonstrated its regulatory potency in cellular energy homeostasis and immune system gene expression through inhibiting Nlrp3 and Tlr4 overexpression. Furthermore, failure in energy production as the key factor in various psychiatric disorders was reversed by apigenin modulating effect on AMPK gene expression. Overall, 20 mg/kg of apigenin was recognized as the dose suitable for minimizing the undesirable adverse effects in the STZ-mediated depression model proposed in this study. Our data suggested that apigenin could be able to adjust behavioral dysfunction, biochemical biomarkers and recovered cellular antioxidant level in depressed animals. The surprising results were achieved by raise in COQ10 level, which could regulate the overexpression of the AMPK gene in stressful conditions. The regulatory effect of apigenin in inflammatory signaling pathways such as Nlrp3, and Tlr4 gene expression was studied at the surface part of the hippocampus.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Apigenin; Depression; Immune system; Oxidative stress; Streptozotocin

Mesh:

Substances:

Year:  2021        PMID: 34705188     DOI: 10.1007/s11064-021-03473-0

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  45 in total

Review 1.  Beyond the serotonin hypothesis: mitochondria, inflammation and neurodegeneration in major depression and affective spectrum disorders.

Authors:  Ann Gardner; Richard G Boles
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2010-08-05       Impact factor: 5.067

2.  Intracerebroventricular Administration of Streptozotocin as an Experimental Approach to Depression: Evidence for the Involvement of Proinflammatory Cytokines and Indoleamine-2,3-Dioxygenase.

Authors:  Leandro Cattelan Souza; Cristiano R Jesse; Marcelo Gomes de Gomes; Cristini Escobar Viana; Etiara Mattos; Neici Cáceres Silva; Silvana Peterini Boeira
Journal:  Neurotox Res       Date:  2017-02-02       Impact factor: 3.911

3.  Increased salivary cortisol after waking in depression.

Authors:  Zubin Bhagwagar; Sepehr Hafizi; Philip J Cowen
Journal:  Psychopharmacology (Berl)       Date:  2005-09-29       Impact factor: 4.530

Review 4.  Role of neurotrophic factors in depression.

Authors:  Eero Castrén; Vootele Võikar; Tomi Rantamäki
Journal:  Curr Opin Pharmacol       Date:  2006-10-17       Impact factor: 5.547

5.  Fluoxetine (Prozac) interaction with the mitochondrial voltage-dependent anion channel and protection against apoptotic cell death.

Authors:  Edna Nahon; Adrian Israelson; Salah Abu-Hamad; Shoshan-Barmatz Varda
Journal:  FEBS Lett       Date:  2005-09-12       Impact factor: 4.124

6.  Maternal exposure to silver nanoparticles are associated with behavioral abnormalities in adulthood: Role of mitochondria and innate immunity in developmental toxicity.

Authors:  Shayan Amiri; Aliakbar Yousefi-Ahmadipour; Mir-Jamal Hosseini; Arya Haj-Mirzaian; Majid Momeny; Heshmat Hosseini-Chegeni; Tahmineh Mokhtari; Sharmin Kharrazi; Gholamreza Hassanzadeh; Seyed Mohammad Amini; Somayeh Jafarinejad; Mahmoud Ghazi-Khansari
Journal:  Neurotoxicology       Date:  2018-03-14       Impact factor: 4.294

7.  Depressive-like behaviour induced by an intracerebroventricular injection of streptozotocin in mice: the protective effect of fluoxetine, antitumour necrosis factor-α and thalidomide therapies.

Authors:  Leandro C Souza; Carlos B Filho; Lucian D Fabbro; Marcelo G de Gomes; André T R Goes; Cristiano R Jesse
Journal:  Behav Pharmacol       Date:  2013-04       Impact factor: 2.293

Review 8.  The revised monoamine theory of depression: a modulatory role for monoamines, based on new findings from monoamine depletion experiments in humans.

Authors:  G R Heninger; P L Delgado; D S Charney
Journal:  Pharmacopsychiatry       Date:  1996-01       Impact factor: 5.788

Review 9.  The inflammatory & neurodegenerative (I&ND) hypothesis of depression: leads for future research and new drug developments in depression.

Authors:  Michael Maes; Raz Yirmyia; Jens Noraberg; Stefan Brene; Joe Hibbeln; Giulia Perini; Marta Kubera; Petr Bob; Bernard Lerer; Mario Maj
Journal:  Metab Brain Dis       Date:  2008-12-16       Impact factor: 3.584

10.  Mitochondrial dysfunction bridges negative affective disorders and cardiomyopathy in socially isolated rats: Pros and cons of fluoxetine.

Authors:  Nazanin Sonei; Shayan Amiri; Iman Jafarian; Mahdieh Anoush; Maryam Rahimi-Balaei; Hugo Bergen; Arya Haj-Mirzaian; Mir-Jamal Hosseini
Journal:  World J Biol Psychiatry       Date:  2016-03-31       Impact factor: 4.132

View more
  1 in total

1.  Synergistic deciphering of bioenergy production and electron transport characteristics to screen traditional Chinese medicine (TCM) for COVID-19 drug development.

Authors:  Po-Wei Tsai; Cheng-Yang Hsieh; Jasmine U Ting; Yi-Ru Ciou; Chia-Jung Lee; Chieh-Lun Hsieh; Tzu-Kuan Lien; Chung-Chuan Hsueh; Bor-Yann Chen
Journal:  J Taiwan Inst Chem Eng       Date:  2022-05-12       Impact factor: 5.477

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.